Updated survival results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.

被引：0
|
作者：
Liu, Yue
Ding, Kefeng
Xiao, Qian
He, Jinjie
Hu, Hanguang
Du, Jinlin
Zhu, Yuping
Chen, Jiaqi
Liu, Zhuo
Wang, Jianping
Sun, Lifeng
Xu, Dong
Li, Jun
Liao, Xiujun
Wang, Jianwei
Cai, Yibo
Cai, Cheng
Jin, Zhekang
Yuan, Ying
机构：
[1] Zhejiang Univ, Affiliated Hosp 2, Dept Colorectal Surg & Oncol,Sch Med, Key Lab Canc Prevent & Intervent,Minist Educ, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 2, Dept Med Oncol,Sch Med, Key Lab Canc Prevent & Intervent,Minist Educ, Hangzhou, Zhejiang, Peoples R China
[4] Zhejiang Univ, Colorectal Surg, Jinhua Hosp, Jinhua, Zhejiang, Peoples R China
[5] Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Colorectal Surg, Hangzhou, Zhejiang, Peoples R China
[6] Zhejiang Univ, Affiliated Hosp 2, Dept Med Oncol, Sch Med, Hangzhou, Zhejiang, Peoples R China
[7] Zhejiang Univ, Affiliated Hosp 2, Colorectal Surg & Oncol,Sch Med, Key Lab Canc Prevent & Intervent,Minist Educ, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-492-3532-2370-7650-2700; 283-237-255; 281-206-4957-3975-3408-6824; 261-492-12161; 261-492-2769; 613-135-244-3829; 281-318-430; 5; 4; 2; 2414; 1589; 92; 239; 6; 3; 1; 38116-38094-8; 38092-34311; 38092-29234; 38092-18849;
D O I：
10.1200/JCO.2024.42.3_suppl.131
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：131 / 131
页数：1
相关论文
共 50 条
  • [21] First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Zheng, Bobo
    Wang, Xin
    Wei, Mingtian
    Wang, Quan
    Li, Jiang
    Bi, Liang
    Deng, Xiangbing
    Wang, Ziqiang
    BMC CANCER, 2019, 19 (1)
  • [22] Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients
    Samalin, Emmanuelle
    Mazard, Thibault
    Assenat, Eric
    Rouyer, Magali
    de la Fouchardiere, Christelle
    Guimbaud, Rosine
    Smith, Denis
    Portales, Fabienne
    Ychou, Marc
    Adenis, Antoine
    Fiess, Catherine
    Lopez-Crapez, Evelyne
    Thezenas, Simon
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (08) : 1375 - 1381
  • [23] First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study
    Mendez Mendez, Jose Carlos
    Salgado Fernandez, Mercedes
    de la Camara Gomez, Juan
    Pellon Augusto, Mari Luz
    Covela Rua, Marta
    Quintero Aldana, Guillermo
    Fernandez Montes, Ana
    Reboredo Lopez, Margarida
    Valladares Ayerbes, Manuel
    Jorge Fernandez, Monica
    Gonzalez Villarroel, Paula
    Romero Reinoso, Carlos
    Ramos Vazquez, Manuel
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (08) : 1263 - 1267
  • [24] Phase II trial of modified FOLIRI plus Panitumumab as first-line treatment in elderly patients with RAS wild-type metastatic colorectal cancer.
    Karampeazis, Athanasios
    Vamvakas, Lampros
    Kentepozidis, Nikolaos K.
    Kotsakis, Athanasios
    Kalbakis, Kostas
    Xynogalos, Spyros
    Sougklakos, Ioannis
    Emmanouilides, Christos E.
    Voutsina, Alexandra
    Hatzidaki, Dora
    Georgoulias, Vassilis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registry
    Chen, Chou-Chen
    Chang, Shih-Ching
    Chang, Yu-Yao
    Lin, Bo-Wen
    Chen, Hong-Hwa
    Hsieh, Yao-Yu
    Hsu, Hung-Chih
    Hsieh, Meng-Che
    Ke, Tao-Wei
    Kuan, Feng-Che
    Wu, Chih-Chien
    Lu, Wei-Chen
    Su, Yu-Li
    Liang, Yi-Hsin
    Chen, Joe-Bin
    Huang, Hsuan-Yuan
    Tsai, Hsiang-Lin
    Wang, Jaw-Yuan
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (12):
  • [26] A phaseI/IIa clinical study of cetuximab combined with fruquintinib in the third-line treatment of RAS/BRAF wild-type colorectal cancer.
    Li Yong
    Qu Yan-chun
    Liu Yufeng
    Liu Yi-hong
    Zhu Yan-Juan
    Ye Yongsong
    Chen Xian
    Qu Xin
    Liu Li-Rong
    Li Wenzhu
    Hou Fangfang
    Zhang Haibo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [27] Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis
    Wu, Chih-Chien
    Wang, Jui-Ho
    Lin, Pei-Chin
    Liang, Chun-An
    Huang, Ching-Ying
    Lien, Han-Chu
    Chen, Chung-Yu
    Chou, Kang-Ju
    Su, Yi-Chia
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 145
  • [28] Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
    Patel, Shiven B.
    Gill, David
    Garrido-Laguna, Ignacio
    ONCOTARGETS AND THERAPY, 2016, 9 : 75 - 86
  • [29] Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
    Geoffrey Y. Ku
    Benjamin A. Haaland
    Gilberto de Lima Lopes
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 231 - 238
  • [30] Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
    Ku, Geoffrey Y.
    Haaland, Benjamin A.
    Lopes, Gilberto de Lima, Jr.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 231 - 238
12345